Allakos (ALLK) Projected to Post Quarterly Earnings on Thursday

Allakos (NASDAQ:ALLK) will likely be announcing its earnings results before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.

Allakos Price Performance

NASDAQ:ALLK opened at $0.26 on Wednesday. The business’s 50-day moving average is $0.56 and its two-hundred day moving average is $0.80. Allakos has a 12 month low of $0.23 and a 12 month high of $1.56. The firm has a market capitalization of $22.84 million, a PE ratio of -0.13 and a beta of 0.72.

Wall Street Analyst Weigh In

Several research analysts have commented on ALLK shares. Citizens Jmp lowered Allakos from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 27th. Piper Sandler downgraded Allakos from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 27th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, Allakos has a consensus rating of “Hold” and an average price target of $2.00.

About Allakos

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.